Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colonic Surgical Resection and Ileocolonic Anastamosis : REPREVIO (recurrence prevention with Entyvio)

Phase 4

Completed

• Conditions: Crohn's disease; 10017969

• Registration Number: NL-OMON55604
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

- In the opinion of the investigator, the subject is capable of understanding
and complying with protocol requirements.
- The subject signs and dates a written, informed consent form and any required
privacy authorization prior to the initiation of any study procedures.
- Established Crohn*s disease as the indication for ileocolonic resection
- Age above 18
- Ileocolonic resection with ileocolonic anastomosis and removal of all tissue
macroscopically affected by CD according to the surgeon
- Presence of at least 1 risk factor for recurrence:
• Active smoking more than 10 cigarettes/day
• 2nd, 3rd or later resection
• Surgery for perforating complication (abscess, fistula)
• Previous exposure to anti-TNF antibodies
- Male or non-pregnant, non-lactating females. Females of child bearing
potential must have a negative serum pregnancy test prior to randomization, and
must use a hormonal (oral, implantable or injectable) or barrier method of
birth control throughout the study. Females unable to bear children must have
documentation of such in the source records (i.e., tubal ligation,
hysterectomy, or post-menopausal [defined as a minimum of one year since the
last menstrual period]).
- Anti-TNF discontinued for at least 6 weeks before screening
- Written informed consent must be obtained and documented

Exclusion Criteria

- Patients that need to continue postoperative medication for their CD as per
investigator's discretion, eg for fistulizing perianal CD.
- Previous treatment with vedolizumab
- Clinically significant CD elsewhere in the gastrointestinal tract not removed
with surgery
- Patients with clinically documented short bowel syndrome.
- Patients with a history of cancer (other than resected cutaneous basal or
squamous cell carcinoma or in situ cervical cancer) with less than 2
disease-free documented years.
- Patients with the following laboratory abnormalities:
White blood count < 3 x 109/L
Lymphocyte count < 0.5 x 109/L
Hemoglobin < 8 g/dL
Platelet count < 125 x 109/L or > 800 x 109/L
ALT or AST > 3.0 times the upper limit of normal (ULN)
Alkaline Phosphatase > 2.0 times the ULN
Serum Creatinine > 2 times the ULN
Prothrombin time (INR) > 1.5 times normal
- Active participation in another trial.
- Evidence of Clostridium difficile infection in the previous 4 weeks.
- Patients with abdominal abscess, active or latent tuberculosis or cancer.
- A history of alcohol or illicit drug use that in the opinion of the principal
investigator (PI) would interfere with study procedures.
- Patients with psychiatric problems that in the opinion of the PI would
interfere with study procedures.
- Patients unable to attend all study visits.
- Patients with a history of non-compliance with clinical study protocols.
- Contraindication for endoscopy.
- History of colonic dysplasia/cancer
- Received other biologics within the last 6 weeks of screening
- Known HIV, chronic hepatitis B or C infection
- Evidence of or treatment for C. difficile infection or other intestinal
pathogen at screening

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Proportion of patients with severe endoscopic postoperative recurrence of CD<br /><br>(Rutgeerts i2b, i3 or i4) after approximately 6 months (Week 26). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. The proportion of patients with any endoscopic recurrence of CD (Modified<br /><br>Rutgeerts Grade > i0) after 6 months.<br /><br>2. Changes in the CDAI (Crohn*s disease activity index) and HBI (Harvey<br /><br>Bradshaw index) between week 0 and 26. This measure will give an indication<br /><br>for clinical recurrence. Although most patients will remain asymptomatic, we<br /><br>will collect global scores as well as individual components.<br /><br>3. Adverse events and serious adverse events<br /><br>4. Quality of life measure with a disease-specific instrument (IBDQ) and a<br /><br>generic QoL instrument (SF-36).<br /><br>5. Serum concentrations of vedolizumab and antibodies to vedolizumab before<br /><br>every infusion</p><br>